Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
Stanford University
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04756765CT.gov Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer | — | Withdrawn | — | — | — |
NCT05141708CT.gov Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m | — | Completed | — | — | — |
NCT03990896CT.gov Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial | — | Recruiting | — | — | — |
NCT04690855CT.gov A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer | — | Terminated | — | — | — |
NCT04991480CT.gov A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors | — | Completed | — | — | — |
NCT04819243CT.gov PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study | — | Recruiting | — | — | — |
NCT04849364CT.gov Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer | — | Terminated | — | — | — |
NCT04987931CT.gov Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT04892693CT.gov Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency | — | Recruiting | — | — | — |
NCT04550494CT.gov Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations | — | Recruiting | — | — | — |
Show 11 more trialsShow fewer
NCT04703920CT.gov Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer | — | Completed | — | — | — |
NCT04672460CT.gov A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT04591431CT.gov The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | — | Unknown | — | — | — |
NCT04134884CT.gov Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer | — | Completed | — | — | — |
NCT04039230CT.gov Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer. | — | Active Not Recruiting | — | — | — |
NCT06193525CT.gov FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test | — | Recruiting | — | — | — |
NCT03964532CT.gov TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT03499353CT.gov Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer | — | Terminated | — | — | — |
NCT02401347CT.gov Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors | — | Completed | — | — | — |
NCT01989546CT.gov Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations | — | Completed | — | — | — |
NCT01042379CT.gov I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Talazoparib (this asset) | Stanford University | P2 | CCC · 55 |
| Darolutamide | Vandana Abramson | P2 | BBB |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Trastuzumab Duocarmazine | Byondis B.V. | P3 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Ribociclib | National Cancer Institute (NCI) | P4 | BB |
| Oxaliplatin | Beijing Biostar Pharmaceuticals Co., Ltd. | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Talazoparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| BRCA2-Related Cancer Predisposition | — | P3 | BB · 68 |
| Castration-Resistant Prostate Carcinoma | — | P2 | BB · 65 |
| Her2-Receptor Negative Breast Cancer | — | P2 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Talazoparib in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/talazoparib-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →